Basis of antibody imaging and therapy

The Pathophysiologic Basis of Nuclear Medicine: Second Edition

Volumn , Issue , 2006, Pages 486-495

  Zuckier, Lionel ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867787150     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-47953-6_19     Document Type: Chapter

References (132)

1. Bogard WC Jr, Dean RT, Deo Y, Fuchs R, Mattis JA, McLean AA, et al (1989) Practical consideration in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. Semin Nucl Med 19:202-220
2. Hnatowich DJ (1990) Recent developments in the radiola-beling of antibodies with iodine, indium, and technetium. Semin Nucl Med 20:80-91
3. Hiltunen JV (1993) Search for new and improved radiola-beling methods for monoclonal antibodies. Acta Oncol 32:831-839
4. Zimmer AM, Spies SM (1993) New approaches to radiola-beling monoclonal antibodies. Cancer Treat Res 68:99-109
5. Kassis AI, Adelstein SJ (2005) Radiobiologic principles in radionuclide therapy. J Nucl Med 46 Suppl 1:4S-12S
6. Zuckier LS, DeNardo GL (1997) Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 27:10-29
7. Pinkas L, Robins PD, Forstrom LA, Mahoney DW, Mullan BP (1999) Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Nucl Med Commun 20:689-696
8. Goldenberg DM, Nabi HA (1999) Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med 29:41-48
9. Jhanwar YS, Divgi C (2005) Current status of therapy of solid tumors. J Nucl Med 46 Suppl 1:141S-150S
10. Sharkey RM, Goldenberg DM (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46 Suppl 1:115S-127S
11. Winkelhake JL (1978) Immunoglobulin structure and effector functions. Immunochemistry 15:695-714
12. Burton DR (1985) Immunoglobulin G: functional sites. Mol Immunol 22:161-206
13. Ward ES, Ghetie V (1995) The effector functions of immu-noglobulins: implications for therapy. Ther Immunol 2:77-94
14. Zuckier LS, Rodriguez LD, Scharff MD (1989) Immunolog-ic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 19:166-186
15. Zuckier LS, Chang CJ, Scharff MD, Morrison SL (1998) Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res 58:3905-3908
16. Pollock RR, French DL, Metlay JP, Birshtein BK, Scharff MD (1990) Intravascular metabolism of normal and mutant mouse immunoglobulin molecules. Eur J Immunol 20:2021-2027
17. Waldmann TA, Strober W (1969) Metabolism of immuno-globulins. Progr Allergy 13:1-110
18. Lippincott SW, Korman S, Fong C, et al (1960) Turnover of labeled normal gamma globulin in multiple myeloma. J Clin Invest 39:565-572
19. 131I-labelled gammaglobulin. Acta Med Scand 173:589-603
20. Brambell FWR, Hemmings WA, Morris IG (1964) A theoretical model of t-globulin catabolism. Nature 203: 1352-1355
21. Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the b2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516
22. Ghetie V, Hubbard JG, Kim TK, Tsen MF, Lee Y, Ward ES (1996) Abnormally short serum half-lives of IgG in beta-2-microglobulin-deficient mice. Eur J Immunol 26:690-696
23. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE (1996) Increased clearance of IgG in mice that lack b2-mi-croglobulin: possible protective role of FcRn. Immunology 89:573-578
24. Junghans RP (1997) Finally: The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16:29-57
25. Kim JK, Tsen MF, Ghetie V, Ward ES (1994) Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice. Scand J Immunol 40:457-465
26. Kim J-K, Tsen M-F, Ghetie V, Ward ES (1994) Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol 24:542-548
27. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (Suppl) 50:814s-819s
28. Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1990) A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31: 1191-1198
29. Buchegger F, Halpern SE, Sutherland RM, Schreyer M, Mach J-P (1986) In vitro and in vivo tumor models for studies of distribution of radiolabelled monoclonal antibodies and fragments. Nuklearmedizin 25:207-209
30. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 72:2101-2114
31. Parham P (1983) On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol 131:2895-2902
32. 2. J Nucl Med 24:316-325
33. Thakur ML, Marcus CS, Kipper SL, Ahdoot R, Diggles L, Pham HL, et al (2001) Imaging infection with LeuTech. Nucl Med Commun 22:513-519
34. Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach J-P (1987) Penetration and binding of radiolabeled anti-carci-noembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 47:1627-1633
35. 2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (an-ti-LyB8.2) and irrelevant (MOPC-21) antibodies. J Immunol 139:3041-3049
36. 2, and Fab' in mice. Cancer Res 46:3969-3978
37. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, et al (1989) Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246:1275-1281
38. Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA (1991) Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci USA 88:4363-4366
39. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, No-votny J, Margolies MN, et al (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Esche-richia coli. Proc Natl Acad Sci USA 85:5879-5883
40. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, et al (1988) Single-chain antigen-binding proteins. Science 242:423-426
41. Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, et al (1991) Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51:6363-6371
42. Schlom J (1991) New approaches to improved antibody targeting. Antibody Immunoconjug Radiopharm 4:819-828
43. Pirofski L-A, Casadevall A, Scharff MD (1992) Current state of hybridoma technology. ASM News 58:613-617
44. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402-3408
45. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immuno-globulin variable domains secreted from Escherichia coli. Nature 341:544-546
46. Williams WV, Moss DA, Kieber-Emmons T, Cohen JA, Myers JN, Weiner DB, et al (1989) Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci USA 5537-5541
47. Taub R, Gould RJ, Garsky VM, Cicarone TM, Hoxie J, Friedman PA, et al (1989) A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. J Biol Chem 264:259-265
48. Williams WV, Kieber-Emmons T, VonFeldt J, Greene MI, Weiner DB (1991) Design of bioactive peptides based on antibody hypervariable region structures: Development of conformationally constrained and dimeric peptides with enhanced affinity. J Biol Chem 266:5182-5190
49. Knight LC, Radcliffe R, Maurer AH, Rodwell JD, Alvarez VL (1994) Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets. J Nucl Med 35:282-288
50. Adams GP (1998) Improving the tumor specificity and retention of antibody-based molecules. In Vivo 12:11-22
51. Behr TM, Goldenberg DM, Becker W (2005) Reducing the renal uptake of radiolabeled antibody fragments and pep-tides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25:201-212
52. Macmillan Dictionary of Immunology (1989) Macmillan Press, New York
53. Hornick CL, Karush F (1972) Antibody affinity-III. The role of multivalence. Immunochemistry 9:325-340
54. Crothers DM, Metzger H (1972) The influence of polyva-lency on the binding properties of antibodies. Immunochemistry 9:341-357
55. Kaufman EN, Jain RK (1992) Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 52:4157-4167
56. Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD (2000) Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 60:7008-7013
57. Chapman PB, Lonberg M, Houghton AN (1990) Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res 50: 1503-1509
58. Pollock RR, French DL, Gefter ML, Scharff MD (1988) Identification of mutant monoclonal antibodies with increased antigen binding. Proc Natl Acad Sci USA 85: 2298-2302
59. Schott ME, Frazier KA, Pollack DK, Verbanac KM (1993) Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitu-mor antibody fragments. Bioconjugate Chem 4:153-165
60. King DJ, Turner A, Farnsworth APH, Adair JR, Owens RJ, Pedley RB, et al (1994) Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 54:6176-6185
61. Werlen RC, Lankinen M, Offord RE, Schubiger PA, Smith A, Rose K (1996) Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved bio-distribution and potential for therapeutic application. Cancer Res 56:809-815
62. Wolff EA, Schreiber GJ, Cosand WL, Raff HV (1993) Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 53:2560-2565
63. Smith RIF, Morrison SL (1994) Recombinant polymeric IgG: an approach to engineering more potent antibodies. Bio/Technology 12:683-688
64. Poon PH, Morrison SL, Schumaker VN (1995) Structure and function of several anti-dansyl chimeric antibodies formed by domain interchanges between human IgM and mouse IgG2b. J Biol Chem 270:8571-8577
65. Holliger P, Prospero T, Winter G (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444-6448
66. Adams GP, McCartney JE, Tai M-S, Oppermann H, Huston JS, Stafford WF III, et al (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 Anti-c-erbB-2 single-chain Fv. Cancer Res 53:4026-4034
67. H3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055-3061
68. Adams GP, Schier R, McCall AM, Wolf EJ, Marks JD, Wei-ner LM (1996) Tumor targeting properties of anti-C-ERB-2 single-chain Fv molecules over a wide range of affinities for the same epitope. Tumor Targeting 2:154
69. Buchsbaum DJ (1997) Experimental tumor targeting with radiolabeled ligands. Cancer (Suppl) 80:2371-2377
70. Roselli M, Buonomo O, Piazza A, Guadagni F, Vecchione A, Brunetti E, et al (1998) Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation. Semin Surg Oncol 15:254-262
71. Fischman AJ, Khaw BA, Strauss HW (1989) Quo vadis ra-dioimmune imaging (editorial). J Nucl Med 30:1911-1915
72. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL (1992) Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 52:377-384
73. Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM (1989) Influence of animal host and tumor implantation site on radio-antibody uptake in the GW-39 human colonic cancer xenograft. Int J Cancer 44:1041-1047
74. Riechmann L, Weill M, Cavanagh J (1992) Improving the antigen affinity of an antibody Fv-fragment by protein design. J Mol Biol 224:913-918
75. Suresh MR, Cuello AC, Milstein C (1986) Bispecific monoclonal antibodies from hybrid hybridomas. Methods En-zymol 121:210-228
76. Clark M, Gilliland L, Waldmann H (1988) Hybrid antibodies for therapy. Progr Allergy 45:31-49
77. Phelps JL, Beidler DE, Jue RA, Unger BW, Johnson MJ (1990) Expression and characterization of a chimeric bi-functional antibody with therapeutic applications. J Immunol 145:1200-1204
78. Moran TM, Usuba O, Shapiro E, Rubinstein LJ, Ito M, Bona CA (1990) A novel technique for the production of hybrid antibodies. J Immunol Methods 129:199-205
79. Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, et al (1991) Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging co-lorectal carcinoma. Cancer Res 51:6650-6655
80. LeDoussal J-M, ChetanneauA, Gruaz-GuyonA, MartinM, Gautherot E, Lehur P-A, et al (1993) Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacoki-netics, biodistribution, scintigraphy and immune response. J Nucl Med 34:1662-1671
81. Peltier P, Curtet C, Chatal J-F, LeDoussal J-M, Daniel G, Aillet G, et al (1993) Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 34:1267-1273
82. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, et al (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11:1250-1255
83. Fell HP, Gayle MA, Grosmaire L, Ledbetter JA (1991) Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2. J Immun 146:2446-2452
84. Shin S-U, Morrison SL (1990) Expression and characterization of an antibody binding specificity joined to insulinlike growth factor 1: potential applications for cellular targeting. Proc Natl Acad Sci USA 87:5322-5326
85. Shin S-U, Friden P, Moran M, Olson T, Kang Y-S, Pardridge WM, et al (1995) Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci USA 92:2820-2824
86. Paganelli G, Magnani P, Siccardi AG, Fazio F (1995) Clinical application of the avidin-biotin system for tumor targeting. In: Goldenberg DM (ed) Cancer therapy with ra-diolabeled antibodies. CRC Press, Boca Raton, pp 239-254
87. Paganelli G, Malcovati M, Fazio F (1991) Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. Nucl Med Commun 12:211-234
88. Kalofonos HP, Rusckowski M, Siebecker DA, Sivolapenko GB, Snook D, Lavender JP, et al (1990) Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med 31:1791-1796
89. Hnatowich DJ, Virzi F, Rusckowski M (1987) Investigations of avidin and biotin for imaging applications. J Nucl Med 28:1294-1302
90. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FH (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400-411
91. Hand PH, Kashmiri SVS, Schlom J (1994) Potential for re-combinant immunoglobulin constructs in the management of carcinoma. Cancer (Suppl) 73:1105-1113
92. James K, Bell GT (1987) Human monoclonal antibody production: Current status and future prospects. J Immunol Methods 100:5-40
93. James K (1990) Human monoclonal antibodies and engineered antibodies in the management of cancer. Semin Cancer Biol 1:243-253
94. Steinitz M, Klein G, Koskimies S, Markel O (1977) EB virus-induced B lymphocytic cell lines producing specific antibody. Nature 269:420-422
95. Nakamura M, Burastero SE, Ueki Y, Larrick JW, Notkins AL, Casali P (1988) Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. J Immun 141:4165-4172
96. Kozbor D, Lagarde AE, Roder JC (1982) Human hybrid-omas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci USA 79:6651-6655
97. Ostberg L, Pursch E (1983) Human X (mouse X human) hybridomas stably producing human antibodies. Hybridoma 2:361-367
98. Cote RJ, Morrissey DM, Houghton AN, Thomson TM, Daly ME, Oettgen HF, et al (1986) Specificity analysis of human monoclonal antibodies reactive with cell surface and in-tracellular antigens. Proc Natl Acad Sci USA 83:2959-2963
99. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851-6855
100. Morrison SL (1985) Generations of human monoclonal antibodies reactive with cellular antigens. Science 229: 1202-1207
101. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351-1361
102. Bruggemann M, Winter G, Waldmann H, Neuberger MS (1989) The immunogenicity of chimeric antibodies. J Exp Med 170:2153-2157
103. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525
104. Reichmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332: 323-327
105. Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293-299
106. Wright A, Shin S-U, Morrison SL (1992) Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 12:125-168
107. Verhoeyen M, Milstein C, Winter G (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239:1534-1536
108. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029-10033
109. Roberts S, Cheetham JC, Rees AR (1987) Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering. Nature 328:731-734
110. Co MS, Queen C (1991) Humanized antibodies for therapy. Nature 351:501-502
111. Mosier DE, Gulizia RJ, Baird SM, Wilson DB (1988) Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335:256-259
112. McCune JM, Namikawa R, Kaneshima H, et al (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639
113. Bruggemann M, Neuberger MS (1996) Strategies for expressing human antibody repertoires in transgenic mice. Immunol Today 17:391-397
114. Sastry L, Alting-Mees M, Huse WD, Short JM, Sorge JA, Hay BN, et al (1989) Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: Construction of a heavy chain variable region-specific cDNA library. Proc Natl Acad Sci USA 86:5728-5732
115. Wells JA, Lowman HB (1992) Rapid evolution of peptide and protein binding properties in vitro. Curr Opin Biotechnol 3:355-362
116. Schlom J, Eggensperger D, Colcher D, Molinolo A, Hou-chens D, Miller LS, et al (1992) Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 52:1067-1072
117. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, et al (1998) Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58:485-490
118. Adams GP, Schier R, McCall AM, Simmons H, Horak E, Marks JD, et al (1998) What are the determinants of antibody-based targeting? Proc Am Assoc Cancer Res 39:436
119. Sharkey RM, Goldenberg DM, Goldenberg H, Lee RE, Ballance C, Pawlyk D, et al (1990) Murine monoclonal antibodies against carcinoembryonic antigen: immunologi-cal, pharmacokinetic, and targeting properties in humans. Cancer Res 50:2823-2831
120. Goldenberg DM, Larson SM (1992) Radioimmunodetec-tion in cancer identification. J Nucl Med 33:803-814
121. Weinstein JN, Eger RR, Covell DG, Black CDV, Mulshine J, Carrasquillo JA, et al (1987) The pharmacology of monoclonal antibodies. Ann NY Acad Sci 507:199-210
122. 2, and Fab in tumors. Cancer Res 49:5656-5663
123. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 52:5144-5153
124. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, et al (1988) The intraperitoneal delivery of radiola-beled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 26:187-201
125. Epentos AA, Munro AJ, Stewart S, et al (1987) Antibody-guided irradiation of advanced ovarian cancer with in-traperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890-1899
126. 111 In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Cancer Res 47:6093-6099
127. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon II JE, et al (2005) Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389-1397
128. Guadagni F, Roselli M, Nieroda C, Dansky-Ullmann G, Schlom J, Greiner JW (1993) Biological response modifiers as adjuvants in monoclonal antibody-based treatment. In Vivo 7:591-599
129. LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, et al (1991) Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleu-kin 2 immunoconjugate. Cancer Res 51:2694-2698
130. Sautter-Bihl ML (1994) Radioimmunotherapy with monoclonal antibodies: A new horizon in nuclear medicine therapy. Nucklearmedizin 33:167-173
131. Corcoran MC, Eary J, Bernstein I, Press OW (1997) Ra-dioimmunotherapy strategies for non-Hodgkin's lym-phomas. Ann Oncol (Suppl) 8:S133-S138
132. Zuckier LS (1999) Monoclonal antibodies in oncology. In: Aktolun C, Tauxe WN (eds) Nuclear oncology. Springer, Berlin, pp 359-369